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Abstract 16 
The study of glycoproteins is a rapidly growing field, which is not surprising considering that 17 
approximately 70% of human proteins are glycosylated and that numerous biological 18 
functions are associated to the glycosylation. In this work, our interest focused on the 19 
heterodimeric human Chorionic Gonadotropin (hCG) glycoprotein that is the specific 20 
hormone of the human pregnancy, consisting of an α and a β subunit, so-called hCGα and 21 
hCGβ, respectively. This protein possesses a very high structural heterogeneity, essentially 22 
due to the presence of 8 glycosylation sites, but also other types of post-translational 23 
modifications. In this study, for the first time, the potential of hydrophilic interaction liquid 24 
chromatography (HILIC) was investigated to separate the intact hCG isoforms. Three 25 
different HILIC stationary phases were tested using an hCG-based drug as standard, a 26 
recombinant hCG. For each stationary phase, the effect of the initial mobile phase 27 
composition based on ACN/H2O mixture, the slope of the gradient, the content and nature 28 
of the acidic additive (formic acid and trifluoroacetic acid (TFA)), and the addition of a 29 
volatile salt (ammonium formate) on the retention and the resolution were studied. The 30 
best HILIC separation was obtained with the amide column and a mobile phase composed of 31 
water/ACN containing 0.1% of TFA. The repeatability in terms of retention times and peak 32 
areas was then assessed. Finally, the method was applied to the analysis of a second hCG-33 
based drug obtained from urine of pregnant women. Both drugs gave chromatograms with 34 
more than 10 peaks. However, they were significantly different, which demonstrated the 35 
potential of HILIC method for hCG isoform fingerprinting. 36 
 37 
Keywords: Glycosylation; HILIC chromatography; Human Chorionic Gonadotropin; Intact 38 
protein; Isoforms  39 
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1. Introduction 40 
Human Chorionic Gonadotropin (hCG) constitutes the first hormonal message from the 41 
placenta to the mother, detectable in maternal blood as early as one week after 42 
fecundation, and used in pregnancy diagnosis [1]. This protein is essential for the 43 
development of both placenta and fetus [2]. It is composed of two non-covalently linked 44 
subunits, hCGα and hCGβ. The α-subunit has a molecular weight (MW) of about 10,198 Da 45 
regardless of glycans and 2 N-glycosylation sites and is common to the pituitary 46 
gonadotropin hormones such as the follicle-stimulating hormone, the thyroid-stimulating 47 
hormone, and the luteinizing hormone [3,4]. The β-subunit represents the specific part of 48 
hCG and has a MW of 15,521 Da regardless of glycans and 2 N- and 4 O-glycosylation sites 49 
[5]. Therefore, with 8 glycosylation sites, hCG is a highly heterogeneous protein.  50 
Its characterization was already performed by analysing the glycopeptides obtained after an 51 
enzymatic digestion [6–8] or the released N-glycans after a PNGase-F treatment to obtain 52 
the glycan profiles of hCG-based drugs [5]. Furthermore, one study also demonstrated the 53 
potential of pronase to determine the composition of O-glycans present on the β-subunit 54 
[9]. However, all these approaches are time-consuming, because they require numerous 55 
pre-treatment steps, and they do not give the exact combinations of multiple post-56 
translational modifications (PTMs) of a given isoform. This is why today the fast and cheap 57 
analysis of intact glycoprotein presents a large interest.  58 
High-performance liquid chromatography (HPLC) in combination with UV or mass 59 
spectrometry (MS) detection is now a common approach for the analysis of intact proteins 60 
[10,11]. Recently, we demonstrated the potential of reversed phase liquid chromatography 61 
(RPLC) for the separation of intact hCG isoforms [12]. However, RPLC may lack of selectivity 62 
to separate the hCG glycoforms whereas some papers dealing with other proteins showed 63 
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that it could be performed by hydrophilic interaction liquid chromatography (HILIC) [13–17]. 64 
Indeed, HILIC allowed the monitoring of the glycosylation reaction with different glycans of a 65 
model protein (ribonuclease A) and 2 antigenic proteins hyphenated with UV or MS 66 
detection [13-15]. Periat et al. also demonstrated the potential of HILIC-UV for the quality 67 
control of therapeutic monoclonal antibodies [16]. Recently, Domínguez-Vega et al. 68 
demonstrated that HILIC associated to high-resolution MS allowed the profiling of 69 
interferon-beta-1a and the identification of 12 glycoforms [17]. They characterized also 70 
recombinant human erythropoietin (4 glycosylation sites) and they identified 51 glycoforms 71 
and other PTMs [17]. 72 
Here, for the first time, HILIC was investigated to separate the intact hCG isoforms. The 73 
chromatographic performances of three HILIC-columns (Accucore Amide, Mixed-Mode 74 
HILIC-1, and GlycanPac AXH-1) were compared. The effect of different parameters on the 75 
separation (initial mobile phase composition, slope of the gradient, temperature of analysis, 76 
injection volume, nature and content of salt) were studied for each column. Finally, the best 77 
column with the optimal conditions was used for the analysis of 2 hCG-based drugs 78 
demonstrating the potential of HILIC for hCG isoform fingerprinting. 79 
 80 
2. Materials and methods 81 
2.1. Reagents and analytes 82 
HPLC-grade acetonitrile (ACN) and formic acid (FA) were supplied by Carlo Erba (Val de Reuil, 83 
France). Ammonium formate (AF) and trifluoroacetic acid (TFA) were purchased from Sigma-84 
Aldrich (Saint Quentin Fallavier, France). The ultra-pure water was obtained with a Direct-Q3 85 
UV system (Millipore, Molsheim, France). Ovitrelle® (Serono Europe Ltd., London, UK) and 86 
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Pregnyl® (Organon, Oss, The Netherlands), are drugs based on recombinant hCG (r-hCG) and 87 
urinary hCG (u-hCG), respectively. Ovitrelle® was available as a solution containing 250 µg of 88 
r-hCG, and Pregnyl as a lyophilized powder containing 5000 IU u-hCG (1 IU is equivalent to a 89 
concentration of 0.092 µg L-1 [18,19]). 90 
The Ovitrelle® solution was reconstituted in 0.5 mL of water to obtain a stock solution 91 
containing 500 µg mL-1 of r-hCG. For Pregnyl®, the lyophilized content of each ampoule was 92 
dissolved in 1 ml of water to obtain a concentration of 460 µg mL -1. All the preparations 93 
were aliquoted and stored at -20°C. Before injection, the hCG fractions were washed and 94 
pre-concentrated at 1 mg mL-1 by centrifugation with ultra-centrifugal units (Merck, 95 
Darmstadt, Germany) having a molecular weight cut-off of 10 kDa.  96 
 97 
2.2. Instrumentations and columns 98 
The experiments were carried out with a 1260 Infinity instrument (bio-inert system), 99 
equipped with a quaternary pump, an autosampler, a column oven, and a UV detector 100 
(Agilent Technologies, Les Ulis, France). The three studied HILIC-columns were: Accucore 101 
Amide (150 x 2.1 mm, 2.6 µm, 150 Å), Acclaim Mixed-Mode HILIC-1 (150 x 2.1 mm, 3 µm, 102 
120 Å), and GlycanPac AXH-1 (150 x 2.1 mm, 3 µm, 120 Å), all purchased from ThermoFisher 103 
(Le Pecq, France). The injection volume was fixed at 1 µL and the flow rate at 0.4 mL min-1. 104 
The column temperature was fixed at 50°C for the Acclaim Mixed-Mode HILIC-1 column, and 105 
at 60°C for the two other columns. FA, TFA, and AF were tested in different proportions in 106 
mobile phases composed of acetonitrile and water. Gradient elution conditions were 107 
optimized for each HILIC column. The detection was performed at 214 nm. 108 
 109 
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3. Results and discussions 110 
3.1. Preliminary choices of the mobile and stationary phases 111 
First, we selected different HILIC stationary phases. Only ones with large particle pore sizes 112 
(≥ 120 Å) were considered to avoid exclusion of the isoforms from the pores. The most 113 
commonly used stationary phase for HILIC analysis of intact proteins in literature is amide-114 
bonded silica, which demonstrated a good potential for the protein glycoprofiling [13–17]. 115 
Therefore, an Accucore amide stationary phase with core-shell particles was selected. The 116 
mixed-mode GlycanPac AXH-1 column was also selected, since it was developed for the 117 
separation of uncharged and charged N-glycans combining weak anion exchange and HILIC 118 
mechanisms, although its performance has not been evaluated yet for the separation of 119 
intact proteins. Finally, an Acclaim Mixed-Mode HILIC-1 column based on silica bonded with 120 
an alkyl chain with a diol end group, used mainly for the separation of surfactants [20], was 121 
also selected, although no application to proteins has been reported yet. Therefore, these 122 
three stationary phases are expected to provide quite different retention mechanisms for 123 
the hCG isoforms.  124 
First experiments were achieved with r-hCG used as standard, as it was expected to be the 125 
purest of our two available hCG-based drugs. A mobile phase containing a water/ACN 126 
mixture acidified with 0.1% (v/v) TFA was used, since its strong influence on retention in 127 
HILIC was reported [21]. Indeed, TFA acts as an ion-pairing agent and it generates some 128 
solvating effect that both impact selectivity, retention, resolution, and peak shape [22]. Even 129 
if Periat et al. demonstrated that the temperature does not have a significant impact on the 130 
HILIC separation as on RPLC [16], values between 50 and 65°C were used in HILIC for the 131 
separation of intact glycoproteins [13–17]. Therefore, the column temperature was fixed at 132 
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60°C for the Accucore Amide and GlycanPac AXH-1 columns and at 50°C for the Acclaim 133 
Mixed-Mode HILIC-1 column, which corresponds to the maximal recommended temperature 134 
given by the manufacturer.  135 
 136 
3.2 Injection conditions 137 
The biggest challenge in HILIC for the analysis of intact proteins is the injection conditions, 138 
i.e. to have sample media that do not induce a significant deformation of chromatographic 139 
peaks while allowing the solubilization of the protein without causing its precipitation. 140 
Indeed, the dissolution in a solvent with a high ACN content (e.g. 70-90%) close to the 141 
mobile phase composition cannot be done with proteins, since they precipitate [23]. 142 
Therefore, samples were prepared by dissolving hCG in water containing different ACN 143 
contents (10, 20, and 30%). and by injecting a reduced volume (1 µl, about 0.2% for the 144 
sample-to-column volume ratio) to prevent from the peak deformation induced by the high 145 
percentage of water [24]. It was observed that the chromatographic performances in terms 146 
of efficiencies and retention times did not change (data not shown), confirming the results 147 
of Ruta et al. [24]. Therefore, hCG was dissolved only in water for the rest of the study, thus 148 
ensuring a better stability of hCG samples. 149 
 150 
3.3 Optimization of the gradient for each column 151 
Different initial ACN contents (between 85 and 65%) and slopes of the mobile phase gradient 152 
(from 4.5% down to 0.25% per min) were tested with each HILIC column. Figure 1 presents 153 
the resulting chromatograms obtained with the conditions leading to the best separation for 154 
each column.  155 
 156 
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 157 
Figure 1: Analysis by HILIC of r-hCG with the three tested columns and the most appropriate mobile 158 
phase gradient for each. Mobile phase: 0.1% TFA in H2O/ACN mixture (v/v). (A) Acclaim Mixed-Mode 159 
HILIC-1; Gradient: 90% ACN for 3 min, from 90 to 60% ACN with a slope of 4.5% min-1, (B) GlycanPac 160 
AXH-1; Gradient: from 85 to 40% of ACN with a slope of 1.5%/min and, (C) Accucore Amide; 161 
Gradient: from 85 to 40% of ACN with a slope of 1.5% min-1. r-hCG: 1 mg mL-1 in water. Other 162 
conditions: see experimental section. 163 
 164 
With the Acclaim Mixed-Mode HILIC-1 column, the best separation was achieved by applying 165 
an isocratic elution at 90% ACN for 3 min followed by a gradient from 90 to 60% with a slope 166 
of 4.5% min-1 (Figure 1A). Only two peaks at 8.8 and 9.6 min were observed in these 167 
conditions. With the GlycanPac AXH-1 column (Figure 1B), a mobile phase gradient from 85 168 
to 40% (1.5% per min) gave a better separation than the first column within two distinct 169 
elution zones. Indeed, at least 4 peaks were observed between 7.8 and 9.6 min and a second 170 
large one between 10.1 and 12.9 min but with an insufficient resolution to distinguish peaks. 171 
The best HILIC separation was obtained with the amide-bonded stationary phase (Figure 1C) 172 
as already observed in the literature for other glycoproteins. Using the same mobile phase 173 
gradient as for the GlycanPac AXH-1 column, the separation enabled to distinguish three 174 
elution zones: 19.8-21.8 min, 21.8-23.4 min, and 23.4-25.2 min. For the first zone, 8 peaks 175 
were observed. For the second and the third zones, the presence of several peaks can also 176 
be suspected, but the resolution is still insufficient here. Nevertheless, this stationary phase 177 
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seems to be the most appropriate to separate a very large number of hCG isoforms and 178 
demonstrates the high heterogeneity of this protein. Moreover, the number of peaks 179 
obtained here by the analysis of intact hCG isoforms in HILIC is significantly superior to the 180 
one obtained in RPLC [12]. At this stage, it is possible to assume that each peak may 181 
correspond to at least one isoform, including glycoform or other PTMs. However, the UV 182 
detection does not allow going further in the characterization of hCG isoforms. 183 
 184 
3.4 Test of different additives in the mobile phase 185 
The replacement of 0.1% TFA by 0.1% of FA in the mobile phase was considered. 186 
Unfortunately, the separation of isoforms dramatically dropped for the three HILIC-columns. 187 
Indeed, as shown in Figure 2A that presents a chromatogram obtained using the amide-188 
bonded stationary phase, only one large zone of co-eluting peaks was obtained. For the two 189 
other columns, a single large peak was observed (see Figures S1A and S1B in the 190 
supplementary data). Then, different percentages of FA, from 0.1% to 1%, were tested but 191 
no improvement of the resolution was observed.  192 
Other ionic additives, such as ammonium acetate or ammonium formate, are commonly 193 
used in HILIC because they can reduce the proteins adsorption and modify the solvation 194 
property, affecting the separation mechanism [25]. Therefore, different concentrations of AF 195 
(10, 50, and 100 mM) in the mobile phase were tested. The pH was adjusted in the aqueous 196 
part at 2.2 with FA. With the Acclaim Mixed-Mode HILIC-1 column, no peak was observed 197 
whatever the AF concentration (see Figure S1C). The best separation was obtained with 100 198 
mM AF for the GlycanPac AXH-1 and the Accucore amide columns (Figures S1D and 2B, 199 
respectively), but in both cases only 4 peaks were observed. Therefore, the chromatographic 200 
performances were largely inferior to the ones with 0.1% of TFA in mobile phase, which 201 
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demonstrates (i) the strong influence of TFA on the retention and resolution of hCG isoforms 202 
in HILIC and (ii) that the amide column gave their best separation.  203 
 204 
Figure 2: Effect of different additives in the mobile phase on the HILIC analysis of r-hCG. Mobile 205 
phase: H2O/ACN mixture (pH 2.2) plus (A) 0.1% FA, (B) 1% FA + 100 mM AF, and (C) 0.05% TFA. 206 
Column: Accucore Amide. Gradient: from 85 to 40% of ACN with a slope of 1.5% min-1. r-hCG: 1 mg 207 
mL-1 in water. Other conditions: see experimental section. 208 
 209 
Figure S1: Effect of different additives in the mobile phase on the HILIC analysis of r-hCG. (A, B) 0.1% 210 
of FA and (C,D) 100 mM AF + 1% FA. (A, C) Acclaim Mixed-Mode HILIC-1. (B, D) GlycanPac AXH-1 211 
columns. Gradient: from 85 to 40% of ACN with a slope of 1.5% min-1, Temperature, (A, C) 50°C and 212 
(B, D) 60°C. r-hCG s: 1 mg mL-1 in water. Other conditions: see experimental section  213 
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Finally, as the presence of TFA appears as mandatory in the mobile phase, its percentage 214 
was reduced to 0.05%. If we compare the resulting chromatogram (Figure 2C) to the one 215 
obtained with 0.1% of TFA (Figure 1C), both are similar but with a decrease in resolution 216 
when the TFA content decreases (5 vs 8 peaks were observed for the first elution zone). The 217 
last parameter tested to improve again the separation was a decrease in the flow-rate but 218 
no significant improvement of resolution values was obtained (between 0.91 and 1.10) 219 
whereas the analysis time increased dramatically.  220 
To conclude, the Accucore Amide column with a mobile phase composed of water and ACN 221 
containing 0.1% TFA gave the most efficient separation of hCG isoforms. The resolution 222 
values of the peaks of the first elution zone (between 19.8 and 21.8 min) were calculated 223 
and they are between 0.81 and 1.02 (see Table 1). The repeatability was then assessed. As 224 
shown in Table 1, the relative standard deviation (RSD) values for the retention times was 225 
inferior to 0.84%, which demonstrate the repeatability of this analytical method. The RSD 226 
values for peak areas between 2.5 and 12.3% may demonstrate some instability of the 227 
sample.  228 
Table 1: Resolution and RSD values of the retention times and the areas of the peaks obtained by the 229 
HILIC analysis of r-hCG with the optimized conditions (n=3). r-hCG: 1 mg mL-1 in water. For peak 230 
number: see Figure 3. 231 
Peak number 1 2 3 4 5 6 7 8 9 10 
% RSD tr (%) 0.84 0.70 0.57 0.64 0.66 0.56 0.43 0.84 0.55 0.62 
% RSD Area (%) 12.28 5.40 3.52 2.52 4.80 5.23 7.54 8.05 10.23 12.25 
Resolution   - 0.90 0.97 0.85 0.94 0.88 0.81 1.02 - -  
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3.5 Analysis of 2 hCG-based drugs  232 
Once the separation parameters were optimized with r-hCG, a second hCG-based drug 233 
obtained from urine of pregnant women (u-hCG) was analyzed using the same conditions. As 234 
for r-hCG, Table 2 presents the RSD values of the retention times of the main peaks of u-hCG 235 
and they were between 0.25 and 1.92%. The RSD values for the peak areas were between 236 
3.6 and 14.3%. Chromatograms of u-hCG (Figure 3A) and r-hCG (Figure 3B) are significantly 237 
different. With u-hCG, the separation profile reveals a first elution zone with at least 10 238 
peaks between 18.7 and 21.6 min, partially resolved (0.67 <Rs<0.99, see Table 2), and a 239 
second with one large peak between 23.1 and 25.5 min. Unfortunately, the separation 240 
conditions do not allow the separation of isoforms present in this second zone.  241 
 242 
Table 2: Resolution and RSD values of the retention times and the areas of the peaks obtained from 243 
the HILIC analysis of u-hCG with the optimized conditions (n=3). u-hCG: 1 mg mL-1 in water. For peak 244 
number: see Figure 3. 245 
 246 
 247 
Peak number 1’ 2’ 3’ 4’ 5’ 6’ 7’ 8’ 9’ 10’ 
% RSD tr (%) 0.45 0.92 0.43 0.32 0.34 0.55 0.25 0.47 0.88 0.56 
% RSD Area (%) 5.40 12.50 4.23 3.67 4.25 7.52 2.10 4.21 14.2 6.2 
Resolution   - 0.86 0.86 0.99 0.80 0.67 0.80 0.86 0.76 -  
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 248 
Figure 3: Superposition of the (A) u-hCG and (B) r-hCG HILIC chromatograms. Accucore Amide 249 
column. Mobile phase: 0.1% TFA in H2O /ACN mixture (v/v). Gradient: from 85 to 40% of ACN with a 250 
slope of 1.5% min-1. r- and u-hCG: 1 mg mL-1 in water. Other conditions: see experimental section 251 
 252 
Compared with r-hCG, the first and the second elution zones of u-hCG have about the same 253 
range of retention times than those obtained with r-hCG for the first (19.8-21.8 min) and the 254 
third (23.4-25.3 min) elution zones. However, it is worthwhile to notice here that (i) the 255 
retention times for each peak within the first elution zone are different for both drugs, and 256 
that (ii) the second elution zone between 21.8 and 23.4 min present for r-hCG was not 257 
observed on the u-hCG chromatogram. Therefore, these results clearly revealed the 258 
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presence of hCG isoforms that differ in number and nature in the two hCG-based drugs. This 259 
HILIC-UV method can therefore easily distinguish the two drugs, with a relatively short 260 
analysis time (26 min) and reasonable cost, and could be used for quality control of hCG-261 
based drugs or fingerprinting studies in real biological samples.  262 
 263 
4. Conclusions  264 
For the first time, the potential of HILIC was evaluated for the separation of the isoforms of 265 
the highly glycosylated hCG at the intact level. Despite the different analytical challenges of 266 
the HILIC mode for the analysis of intact protein such as injection conditions, it was 267 
demonstrated that the amide HILIC-column is able to resolve numerous hCG isoforms. 268 
Despite uncomplete resolution of this method, its potential for fingerprinting approach was 269 
demonstrated. If a higher level of information is necessary, such as the number of 270 
glycoforms, their composition, their structure, and the presence of other types of PTMs, the 271 
hyphenation with high resolution MS is mandatory. This constitutes the next step of this 272 
study. 273 
 274 
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